# Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients

Study · id `cardio:ct-nct06417489` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06417489](<https://clinicaltrials.gov/study/NCT06417489>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06417489

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT06417489. Randomized; no masking; primary purpose treatment. Start 2024-05-31 (anticipated); primary completion 2026-05-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT06417489, source copy `cardio:ctgov-nct06417489-2024-05-16`, retrieved 2026-10-26)
- Planned start: 2024-05-31 (anticipated) (ClinicalTrials.gov record NCT06417489, source copy `cardio:ctgov-nct06417489-2024-05-16`, retrieved 2026-10-26)
- Primary completion: 2026-05-30 (anticipated) (ClinicalTrials.gov record NCT06417489, source copy `cardio:ctgov-nct06417489-2024-05-16`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06417489, source copy `cardio:ctgov-nct06417489-2024-05-16`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06417489-2024-05-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients
- Condition: Type 2 Diabetes
- Intervention (Drug): Combination therapy
- Intervention (Drug): Sequential treatment group
- Lead sponsor: Peking University First Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Peking University First Hospital (`cardio:org-peking-university-first-hospital`)

## Provenance

Content hash: 7ecf55fedc42f437c142bdf1bc911705166b065e88bb855775b424a1ebd2bf59
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
